Johannes Duell

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

Gilles Salles, Johannes Duell, Eva González‐Barca et al. · The Lancet Oncology · 2020 · 519 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma

Matteo Da Vià, Oliver Dietrich, Marietta Truger et al. · Nature Medicine · 2021 · 328 citations

Life Sciences, Immunology, Oncology +15

Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

Max S. Topp, Johannes Duell, Gerhard Zugmaier et al. · Journal of Clinical Oncology · 2020 · 299 citations

Medicine, Hematology, Pharmacology +16

Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL

Johannes Duell, Marcus Dittrich, Tanja Bedke et al. · Leukemia · 2017 · 270 citations · Full text

Life Sciences, Hematology, Immunology +14

Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Johannes Duell, Kami J. Maddocks, Eva González‐Barca et al. · Haematologica · 2021 · 140 citations · Full text

Medicine, Oncology, Pharmacotherapy +12